GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Corbus Pharmaceuticals Holdings Inc (LTS:0SZI) » Definitions » Total Equity

Corbus Pharmaceuticals Holdings (LTS:0SZI) Total Equity : $142.43 Mil (As of Dec. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Corbus Pharmaceuticals Holdings Total Equity?

Corbus Pharmaceuticals Holdings's total equity for the quarter that ended in Dec. 2024 was $142.43 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.


Corbus Pharmaceuticals Holdings Total Equity Historical Data

The historical data trend for Corbus Pharmaceuticals Holdings's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Corbus Pharmaceuticals Holdings Total Equity Chart

Corbus Pharmaceuticals Holdings Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 45.28 69.11 32.99 -6.91 142.43

Corbus Pharmaceuticals Holdings Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -6.91 96.97 125.54 150.50 142.43

Corbus Pharmaceuticals Holdings Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Corbus Pharmaceuticals Holdings's Total Equity for the fiscal year that ended in Dec. 2024 is calculated as

Total Equity=Total Assets(Q: Dec. 2024 )-Total Liabilities(Q: Dec. 2024 )
=155.879-13.451
=142.43

Corbus Pharmaceuticals Holdings's Total Equity for the quarter that ended in Dec. 2024 is calculated as

Total Equity=Total Assets(Q: Dec. 2024 )-Total Liabilities(Q: Dec. 2024 )
=155.879-13.451
=142.43

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Corbus Pharmaceuticals Holdings Total Equity Related Terms

Thank you for viewing the detailed overview of Corbus Pharmaceuticals Holdings's Total Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Corbus Pharmaceuticals Holdings Business Description

Traded in Other Exchanges
Address
500 River Ridge Drive, Norwood, MA, USA, 02062
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.

Corbus Pharmaceuticals Holdings Headlines

No Headlines